KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) EBITDA Margin: 2017-2024

Historic EBITDA Margin for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -4,378.67%.

  • Aquestive Therapeutics' EBITDA Margin fell 3562.00% to -120.61% in Q3 2025 from the same period last year, while for Sep 2025 it was 524.32%, marking a year-over-year increase of 58407.00%. This contributed to the annual value of -4,378.67% for FY2024, which is 436311.00% down from last year.
  • Per Aquestive Therapeutics' latest filing, its EBITDA Margin stood at -4,378.67% for FY2024, which was down 28,043.11% from -15.56% recorded in FY2023.
  • Aquestive Therapeutics' 5-year EBITDA Margin high stood at -15.56% for FY2023, and its period low was -4,378.67% during FY2024.
  • Its 3-year average for EBITDA Margin is -1,502.78%, with a median of -114.11% in 2022.
  • Per our database at Business Quant, Aquestive Therapeutics' EBITDA Margin skyrocketed by 125,581bps in 2021 and then plummeted by 436,311bps in 2024.
  • Yearly analysis of 5 years shows Aquestive Therapeutics' EBITDA Margin stood at -1,394.58% in 2020, then skyrocketed by 125,581bps to -138.77% in 2021, then skyrocketed by 2,465bps to -114.11% in 2022, then skyrocketed by 9,856bps to -15.56% in 2023, then crashed by 436,311bps to -4,378.67% in 2024.